nature portfolio

Corresponding author(s):	Dr Zhenhui Lu
Last updated by author(s):	Aug 4, 2022

Reporting Summary

Nature Portfolio wishes to improve the reproducibility of the work that we publish. This form provides structure for consistency and transparency in reporting. For further information on Nature Portfolio policies, see our <u>Editorial Policies</u> and the <u>Editorial Policy Checklist</u>.

Sta	atisti	CS				
For	all stat	istical ar	nalyses, confirm that the following items are present in the figure legend, table legend, main text, or Methods section.			
n/a	Confi	rmed				
	Х т	he exact	sample size (n) for each experimental group/condition, given as a discrete number and unit of measurement			
	A	stateme	ent on whether measurements were taken from distinct samples or whether the same sample was measured repeatedly			
	The statistical test(s) used AND whether they are one- or two-sided Only common tests should be described solely by name; describe more complex techniques in the Methods section.					
X	A description of all covariates tested					
X	A description of any assumptions or corrections, such as tests of normality and adjustment for multiple comparisons					
\boxtimes	A full description of the statistical parameters including central tendency (e.g. means) or other basic estimates (e.g. regression coefficient AND variation (e.g. standard deviation) or associated estimates of uncertainty (e.g. confidence intervals)					
\boxtimes	For null hypothesis testing, the test statistic (e.g. <i>F</i> , <i>t</i> , <i>r</i>) with confidence intervals, effect sizes, degrees of freedom and <i>P</i> value noted <i>Give P values as exact values whenever suitable.</i>					
\boxtimes	For Bayesian analysis, information on the choice of priors and Markov chain Monte Carlo settings					
\boxtimes						
\boxtimes	E:	stimates	of effect sizes (e.g. Cohen's d, Pearson's r), indicating how they were calculated			
	'		Our web collection on <u>statistics for biologists</u> contains articles on many of the points above.			
So	ftwa	ire an	d code			
Poli	cy info	rmation	about <u>availability of computer code</u>			
Da	ata coll	lection	None			
Da	ata ana	alysis	None			
			g custom algorithms or software that are central to the research but not yet described in published literature, software must be made available to editors and encourage code deposition in a community repository (e.g. GitHub). See the Nature Portfolio guidelines for submitting code & software for further information.			

Data

Policy information about <u>availability of data</u>

All manuscripts must include a <u>data availability statement</u>. This statement should provide the following information, where applicable:

- Accession codes, unique identifiers, or web links for publicly available datasets
- A description of any restrictions on data availability
- For clinical datasets or third party data, please ensure that the statement adheres to our policy

Provide your data availability statement here.

Human rese	arch parti	cipants
Policy information	about <u>studies ir</u>	volving human research participants and Sex and Gender in Research.
Reporting on sex	and gender	None
Population chara		None
Recruitment		None
Ethics oversight	ation on the envis	None
Note that full informa	ation on the appro	oval of the study protocol must also be provided in the manuscript.
Field-spe	ecific re	porting
Please select the or	ne below that is	the best fit for your research. If you are not sure, read the appropriate sections before making your selection.
Life sciences	В	ehavioural & social sciences
For a reference copy of t	the document with a	all sections, see <u>nature.com/documents/nr-reporting-summary-flat.pdf</u>
Life scier	nces stu	ıdy design
All studies must dis	close on these	points even when the disclosure is negative.
Sample size	The sample size	s were chosen according to the literature reports.
Data exclusions	None	
Replication	All attempts at r	replication were successful.
Randomization	The samples/organisms/participants were allocated into experimental groups using random number table.	
Blinding	The investigator	s were blinded to group allocation during data collection and /or analysis.
Reportin	g tor sp	ecific materials, systems and methods
		about some types of materials, experimental systems and methods used in many studies. Here, indicate whether each material, your study. If you are not sure if a list item applies to your research, read the appropriate section before selecting a response.
Materials & exp	perimental sy	ystems Methods
n/a Involved in th	•	n/a Involved in the study
Antibodies Fukaryatia		ChIP-seq
Eukaryotic Palaeontol	ogy and archaeol	□
	nd other organism	

Antibodies

Antibodies used

Clinical data

Dual use research of concern

Antibodies used: describe all antibodies used in the study; as applicable, provide supplier name, catalog number, clone number, and lot number.

Primary anti-bodies against MMP-13 (BA2204, Boster, Wuhan, China), TNF- α (bs-10802R, Bioss, Peking, China), IL-6 (BA4339, Boster, Wuhan, China), SOD1 (bs-1079R, Bioss, Peking, China), GSH (bs-11756R, Bioss, Peking, China) and NRF2 (66504-1-lg, Proteintech, Wuhan, China) were used.

Validation

Describe the validation of each primary antibody for the species and application, noting any validation statements on the manufacturer's website, relevant citations, antibody profiles in online databases, or data provided in the manuscript.

Animals and other research organisms

Policy information about studies involving animals; ARRIVE guidelines recommended for reporting animal research, and Sex and Gender in Research

Laboratory animals	SD rats 3-7 days old were used for Chondrocytes isolation and 3 months old were used for in vivo study.
Wild animals	None
Reporting on sex	The suckling rat used for chondrocytes isolation is not limited by gender. Only the male rats were used for in vivo study.
Field-collected samples	At the end of the experiments, the samples of total joints of the rats were collected by injecting overdose of anesthesia.
Ethics oversight	All experiments involved with animals were performed following the Animal Ethics Committee standards of the Guangxi Medical University.

Note that full information on the approval of the study protocol must also be provided in the manuscript.

Flow Cytometry

Plots

Confirm that:

- The axis labels state the marker and fluorochrome used (e.g. CD4-FITC).
- The axis scales are clearly visible. Include numbers along axes only for bottom left plot of group (a 'group' is an analysis of identical markers).
- All plots are contour plots with outliers or pseudocolor plots.
- A numerical value for number of cells or percentage (with statistics) is provided.

Methodology

Sample preparation	Chondrocytes were obtained from SD rats. Cells were washed by PBS and the incubated with serum medium containing 10 nmol/L of fluorescent 2, 7-dichlorodihydrofluorescein diacetate kit (DCFH-DA; Beyotime, Shanghai, China) at 37°C for 30 min. After washed with PBS, the intracellular ROS were detected by a Flow Cytometer.
Instrument	Data collection was used a Flow Cytometer (BD Calibur).
Software	CellQuest was used to collect and analyze the flow cytometry data.
Cell population abundance	Cell population used for Flow Cytometry is 10*6/mL. The purities of the samples are 97.33 %, 98.19 %, 98.19 %, 98.95 % and 98.35 % for P, PF, PGF, PPF and PPGF, respectively.
Gating strategy	In the scatterplot of FSC vs SSC, circle the main cell population R1 to be analyzed, thereby excluding cell debris and noise signals caused by laser background from the analysis area. The blank cells unlabeled with the fluorescent probe were used as a control to set a gate, and the cell group R2 with green fluorescence was circled.